This study was done in research institute of nuclear medicine from 1988-1992 for evaluation of the value of serum thyroglobulin level in comparison with 1-131 whole body scan (1-131 WBS) in patients with differentiated thyroid carcinoma. 204 patients who had total or near total thyroidectomy treated with 1-131 were evaluated in this study. Out of 204 patients 136 di...

This is a retrospective study on clinical course and treatment response of patients with thyroid hot nodule, referred to nuclear medicine department of Shariati Hospital from 1360 to 1377. From the total 58 patients with average age of 43 yr and incidence peak of 40 yr, 81% were female and 19% were male. 64% of the patients were thyrotoxic and 36% were euthyroid at presentation. Thyrotoxi...

Neuroblastoma, which derives from neural crest, is the most common extracranial solid cancer in childhood. The tumors express the norepinephrine (NE) transporters on their cell membrane and take in metaiodobenzylguanidine (MIBG) via a NE transporter. Since iodine-131 (I-131) MIBG therapy was firstly reported, many trails of MIBG therapy in patients with neuroblastoma were performed. Though mono...

BACKGROUND Like stable iodine, radioiodines concentrate in the thyroid gland, increasing thyroid cancer risk in exposed children. Data on exposure to the embryonic/fetal thyroid are rare, raising questions about use of iodine 131 (I-131) in pregnant women. We present here estimated risks of thyroid disease from exposure in utero to I-131 fallout from the Chernobyl nuclear accident. METHODS We...

BACKGROUND Low iodine diet (LID) is recommended in patients with differentiated thyroid cancer before radioiodine administration. Patients with increased thyroglobulin (Tg) level, but negative (131)I whole body scan present diagnostic and therapeutic dilemma. This study was designed to evaluate the benefit of a two-week LID in patients with elevated serum Tg levels and negative (131)I whole bod...

OBJECTIVE To compare the probe detection method with the image quantification method when estimating (131)I biokinetics and radiation doses to the red marrow and whole body in the treatment of thyroid cancer patients. MATERIALS AND METHODS Fourteen patients with metastatic thyroid cancer, without metastatic bone involvement, were submitted to therapy planning in order to tailor the therapeuti...

UNLABELLED Prestimulation with recombinant human thyroid-stimulating hormone (rhTSH) augments radioiodine (131)I therapy for benign nontoxic multinodular goiter. The purpose of this study was to determine the optimal time interval between rhTSH and (131)I administration to enhance thyroid radioactive iodine uptake (RAIU). METHODS Patients were randomized, in a 2-factorial design, to receive e...

Ionizing radiation in differentiated thyroid cancer (DTC) patients treated with radioiodine (131-I) produces reactive oxygen species (ROS), which could induce oxidative stress with disturbance of redox balance. The aim of this study was to evaluate oxidative stress in DTC patients treated with 3.7 or 5.5 GBq of 131-I using values for serum malondialdehyde (MDA, a marker of oxidative stress), ur...

BACKGROUND (131)I and (211)At are used in nuclear medicine and accumulate in the thyroid gland and may impact normal thyroid function. The aim of this study was to determine transcriptional profile variations, assess the impact on cellular activity, and identify genes with biomarker properties in thyroid tissue after (131)I and (211)At administration in mice. METHODS To further investigate th...